Palavra-chave: IMATINIB

F359V TRANSPORTER GENES CML PHARMAECONOMIC STUDY CHRONIC MYELOID LEUCEMIA (CML) LOW EDUCATION LEVEL DASATINIB-TREATED CYTARABINE CHRONIC MEYLOID LEUKEMIA CHRONIC MYELOID LEUKAEMIA NILOTINIB GENERIC LEUCEMIA MIELÓDE CRÔNICA TREATMENT-FREE REMISSION DISCONTINUATION CYTOGENETIC REMISSION NON-MYELOABLATIVE BCL/ABL POLYMORPHISMS CITARABINA BCR/ABL BCR-ABL MUTATIONS CHRONIC MYELOGENOUS LEUKEMIA MITOXANTRONE BCR-ABL RNAS CHRONIC MYELOID LEUCEMIA LEUCEMIA MIELOIDE CRÔNICA PROTEIN-CODING LASOR MR4.5 MYELOGENOUS LEUKEMIA CHRONIC PHASE CRONIC LYMPHOCYTIC LEUKEMIA START LEUCEMIA MIELÓIDE CRÔNICA (LMC) CML-CP IRS-1 BCR/ABL GENE MESILATO LALNET DASATINIB CHILDREN AND ADOLESCENTS K562 CELLS PHASE 2 STEM CELL TRANSPLANTATION TYROSINE KINASE INHIBITORS EUTOS SCORE LEUCEMIA MIELÓIDE CRÔNICA ANEMIA FALCIFORME LEUCEMIA MIELÓIDE CRÔNICA (LMC-PB) CHRONIC MYELOID LEUKEMIA OCULAR MOLECULAR MOLECULAR RESPONSE FIRST-LINE BRAZIL KIT K5091 FRONTLINE CYTOGENETIC OBSERVATIONAL